10 clinical trials to watch in the 1st 50 percent of 2025 Anticipated readouts in diabetes, cancer and despair headline a series of research results which could support the biotechnology sector regain its footing following a shaky 12 months.It’s even more effective than its rival, semaglutide, promoted as copyright for type 2 diabetes and Wegovy